Issues related to iron replacement in chronic kidney disease

Seminars in Nephrology

Volumn 22, Issue 6, 2002, Pages 479-487

  Agarwal, Rajiv ^a,b   Warnock, David ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; IRON; IRON DEXTRAN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ARTHRALGIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIARRHEA; DRUG APPROVAL; DRUG HYPERSENSITIVITY; FEVER; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOTENSION; INFECTION; IRON ABSORPTION; IRON DEFICIENCY; KIDNEY INJURY; MALAISE; MYALGIA; OSTEOMALACIA; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; URTICARIA; VOMITING; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; IRON DEFICIENCY ANEMIA;

ANEMIA, IRON-DEFICIENCY; CLINICAL TRIALS; ERYTHROPOIETIN, RECOMBINANT; HUMANS; INFECTION; IRON; KIDNEY FAILURE, CHRONIC; OXIDATIVE STRESS;

EID: 0036849549     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1053/snep.2002.35972     Document Type: Article

References (55)

1. Hsu CY, McCulloch CE, Curhan GC: Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 13:504-510, 2002
2. National Kidney Foundation: IV. NKF-K/DOQ1 clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis 37:S182-S238, 2001
3. Looker AC, Dallman PR, Carroll MD, et al: Prevalence of iron deficiency in the United States. JAMA 277:973-976, 1997
4. van Hoek R, Conrad ME Jr: Iron absorption. Measurement of ingested iron-59 by a human whole-body liquid scintillation counter. J Clin Invest 40:1153-1159, 1961
5. Crosby WH, O'Neil-Cutting MA: A small-dose iron tolerance test as an indicator of mild iron deficiency. JAMA 251:1986-1987, 1984
6. Eschbach JW, Cook JD, Scribner BH, et al: Iron balance in hemodialysis patients. Ann Intern Med 87:710-713, 1977
7. Ifudu O, Dawood M, Friedman EA: Relative contributions of body iron status and uremia severity to anemia in patients with advanced chronic renal failure. Nephron 77:315-318, 1997
8. Silverberg DS, Blum M, Schwartz D, et al: Anemia in the predialysis period treated with iron. Semin Dialysis 12:262-266, 1999
9. Rosenblatt SG, Drake S, Fadem S, et al: Gastrointestinal blood loss in patients with chronic renal failure. Am J Kidney Dis 1:232-236, 1982
10. Margolis DM, Saylor JL, Geisse G, et al: Upper gastrointestinal disease in chronic renal failure. A prospective evaluation. Arch Intern Med 138:1214-1217, 1978
11. , Zuckerman GR, Cornette GL, Clouse RE, et al: Upper gastrointestinal bleeding in patients with chronic renal failure. Ann Intern Med 102:588-592, 1985
12. Bainton DF, Finch CA: The diagnosis of iron deficiency anemia, Am J Med 37:62-70, 1964
13. Fudin R, Jaichenko J, Shostak A, et al: Correction of uremic iron deficiency anemia in hemodialyzed patients: A prospective study. Nephron 79:299-305, 1998
14. Schustack A, Meshiaj D, Waiss Z, et al: Intramuscular iron replenishment and replacement combined with testosterone enanthate in maintenance hemodialysis anemia: A follow-up of up to 8 years on 16 patients. Clin Nephrol 23:303-306, 1985
15. Akmal M, Sawelson S, Karubian F, et al: The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure (CRF), or receiving dialytic therapy. Clin Nephrol 42:198-202, 1994
16. Silverberg DS, Blum M, Agbaria Z, et al: Intravenous iron for the treatment of predialysis anemia. Kidney Int Suppl 69:S79-S85, 1999
17. Fishbane S, Shapiro W, Dutka P, et al: A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 60:2406-2411, 2001
18. Saito M, Sugiyama-Okano H, Tsuchiya K, et al: Estimation of iron status by measuring the content of reticulocyte hemoglobin (CHr) in chronic renal failure patients, Proceedings of the 11th International Congress on Nutrition and Metabolism in Renal Disease 60:2002 (abstr)
19. Kausz AT, Obrador GT, Pereira BJ: Anemia management in patients with chronic renal insufficiency. Am J Kidney Dis 36:S39-S51, 2000
20. Chandra RK: Reduced bactericidal capacity of polymorphs in iron deficiency. Arch Dis Child 48:864-866, 1973
21. Finch CA, Miller LR, Inamdar AR, et al: Iron deficiency in the rat. Physiological and biochemical studies of muscle dysfunction. J Clin Invest 58:447-453, 1976
22. Major A, Mathez-Loic F, Rohling R, et al: The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin. Br J Haematol 98:292-294, 1997
23. Fishbane S, Maesaka JK: Iron management in end-stage renal disease. Am J Kidney Dis 29:319-333, 1997
24. Silverberg DS, Iaina A, Peer G, et al: Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 27:234-238, 1996
25. Stoves J, Inglis H, Newstead CG: A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 16:967-974, 2001
26. Silverberg DS, Blum M, Agbaria Z, et al: The effect of i.v. iron alone or in ombination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol 55:212-219, 2001
27. Panesar A, Agarwal R: Safety and efficacy of sodium ferric gluconate complex in patients with chronic kidney disease. Am J Kidney Dis 2002 (in press)
28. Dahdah K, Patrie JT, Bolton WK: Intravenous iron dextran treatment in predialysis patients with chronic renal failure. Am J Kidney Dis 36:775-782, 2000
29. Michael B, Coyne DW, Fishbane S, et al: Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int 61:1830-1839. 2002
30. Faich G, Strobos J: Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans [see comments]. Am J Kidney Dis 33:464-470, 1999
31. Fletes R, Lazarus JM, Gage J, et al: Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 3:743-749, 2001
32. Bailie GR, Johnson CA, Mason NA: Parenteral iron use in the management of anemia in end-stage renal disease patients. Am J Kidney Dis 35:1-12, 2000
33. Auerbach M, Witt D, Toler W. et al: Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med 111:566-570, 1988
34. Horl WH: Should we still use iron dextran in hemodialysis patients? Am J Kidney Dis 37:859-861, 2001
35. Nissenson AR, Lindsay RM, Swan S, et al: Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American clinical trial. Am J Kidney Dis 33:471-482, 1999
36. Charytan C, Levin N, Al Saloum M, et al: Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis 37:300-307, 2001
37. Van Wyck DB, Cavallo G, Spinowitz BS, et al: Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 36:88-97, 2000
38. Sunder-Plassmann G, Horl WH: Safety of intravenous injection of iron saccharate in haemodialysis patients. Nephrol Dial Transplant 11:797-1802, 1996
39. Hoigne R, Breymann C, Kunzi UP. et al: [Parenteral iron therapy: Problems and possible solutions]. Schweiz Med Wochenschr 128:528-535, 1998
40. Chandler G, Harchowal J, Macdougall IC: Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis 38:988-991, 2001
41. Ahsan N: Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: A single center comparative study. J Am Soc Nephrol 9:664-668, 1998
42. Parkkinen J, von Bonsdorff L, Peltonen S, et al: Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 15:1827-1834, 2000
43. Danielson BG, Salmonson T, Derendorf H, et al: Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung 46:615-621, 1996
44. Roob JM, Khoschsorur G, Tiran A, et al: Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 11:539-549, 2000
45. Eiselt J, Racek J, Trefil L, et al: Ferric saccharate infusion enhances lipid peroxidation in hemodialysis patients. Nephrol Dial Transplant 16:141, 2001 (abstr)
46. Mimic-Oka J, Dimkovic N, Radojevic-Savic A, et al: Does iron supplementation aggravate oxidative stress in hemodialysis patients? Nephrol Dial Transplant 16:91, 2001 (abstr)
47. Gery R, Grinberg N, Michelis R, et al: The effect of intravenous iron replacement therapy on protein oxidation in hemodialysis patients. J Am Soc Nephrol 12:380, 2001 (abstr)
48. Sato K, Shiraki M: Saccharated ferric oxide-induced osteomalacia in Japan: Iron-induced osteopathy due to nephropathy. Endocrinol J 45:431-439, 1998
49. Anderson GJ: Non-transferrin-bound iron and cellular toxicity. J Gastroenterol Hepatol 14:105-108, 1999
50. Shah SV: Role of iron in progressive renal disease. Am J Kidney Dis 37:S30-S33, 2001
51. Patruta SI, Edlinger R, Sunder-Plassmann G, et al: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 9:655-663, 1998
52. Damaian D, Hollo Z, Salomone M, et al: IV iron supply in hemodialysis patients: Iron-saccarate or iron-gluconate? Nephrol Dial Transplant 16:132, 2001 (abstr)
53. Kletzmayr J, Horl WH: Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant 17:25-29, 2002 (suppl 2)
54. Feldman HI, Santanna J, Guo W, et al: Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 13:734-744, 2002
55. Feldman HI, Santanna J, Guo W, et al: Parenteral iron administration and survival in hemodialysis. J Am Soc Nephrol 12:327, 2001 (abstr)